Published in Am J Respir Crit Care Med on May 03, 2012
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF) | NCT00957242
Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med (2013) 2.86
Evolving therapies for liver fibrosis. J Clin Invest (2013) 2.59
Thyroid Disease Is Prevalent and Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. Chest (2015) 2.02
Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med (2013) 1.89
Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med (2015) 1.52
Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. Chest (2014) 1.51
Is warfarin the right anticoagulant in idiopathic pulmonary fibrosis? Am J Respir Crit Care Med (2012) 1.40
A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis (2013) 1.18
Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin? Am J Respir Crit Care Med (2013) 1.09
FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis. Am J Pathol (2013) 1.04
New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med (2014) 1.02
TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice. J Clin Invest (2014) 0.98
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup? Am J Respir Crit Care Med (2013) 0.95
Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel Ther (2012) 0.93
Update on diagnosis and treatment of idiopathic pulmonary fibrosis. J Bras Pneumol (2015) 0.92
Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2015) 0.91
Mechanisms of alveolar epithelial injury, repair, and fibrosis. Ann Am Thorac Soc (2015) 0.91
The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes (2014) 0.87
Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. Multidiscip Respir Med (2012) 0.87
The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep (2014) 0.86
Rationale for anticoagulant therapy of pulmonary fibrosis. Am J Respir Crit Care Med (2014) 0.86
Recommendations on treatment for IPF. Respir Res (2013) 0.86
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. Biomed Res Int (2015) 0.83
Acute exacerbations in patients with idiopathic pulmonary fibrosis. Respir Res (2013) 0.83
Pathogenesis of idiopathic pulmonary fibrosis: review of recent findings. F1000Prime Rep (2014) 0.83
Salidroside protects against bleomycin-induced pulmonary fibrosis: activation of Nrf2-antioxidant signaling, and inhibition of NF-κB and TGF-β1/Smad-2/-3 pathways. Cell Stress Chaperones (2015) 0.83
IPF clinical trial design and endpoints. Curr Opin Pulm Med (2014) 0.83
Diagnosis and management of interstitial lung disease. Transl Respir Med (2014) 0.83
Idiopathic pulmonary fibrosis: early detection and referral. Respir Med (2014) 0.82
The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis. Clin Pulm Med (2014) 0.82
Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. Ann Med (2015) 0.81
Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design? Drug Des Devel Ther (2014) 0.81
Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis (2015) 0.80
Interstitial lung disease: raising the index of suspicion in primary care. NPJ Prim Care Respir Med (2014) 0.80
Increased platelet reactivity in idiopathic pulmonary fibrosis is mediated by a plasma factor. PLoS One (2014) 0.80
Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies. J Thorac Dis (2015) 0.80
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med (2016) 0.79
New perspectives on management of idiopathic pulmonary fibrosis. Ther Adv Chronic Dis (2016) 0.79
New approaches to modulating idiopathic pulmonary fibrosis. Curr Allergy Asthma Rep (2013) 0.79
Managing comorbidities in idiopathic pulmonary fibrosis. Int J Gen Med (2015) 0.79
Microhemorrhage is an early event in the pulmonary fibrotic disease of PECAM-1 deficient FVB/n mice. Exp Mol Pathol (2014) 0.78
The diagnosis and treatment of idiopathic pulmonary fibrosis. Dtsch Arztebl Int (2013) 0.78
Procoagulant, tissue factor-bearing microparticles in bronchoalveolar lavage of interstitial lung disease patients: an observational study. PLoS One (2014) 0.77
Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2016) 0.77
Microbes Associate with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med (2017) 0.77
Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin? : a reply to Tzouvelekis. Am J Respir Crit Care Med (2013) 0.76
Recent advances in idiopathic pulmonary fibrosis. Tuberc Respir Dis (Seoul) (2013) 0.76
The clinical assessment of protease-activated receptor-2 expression in inflammatory cells from peripheral blood and bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. Tuberc Respir Dis (Seoul) (2013) 0.76
Idiopathic pulmonary fibrosis complicated by acute thromboembolic disease: chest X-ray, HRCT and multi-detector row CT angiographic findings. J Thorac Dis (2013) 0.75
Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study. Drug Des Devel Ther (2015) 0.75
Interstitial lung diseases: respiratory review of 2013. Tuberc Respir Dis (Seoul) (2013) 0.75
Ambroxol hydrochloride in the management of idiopathic pulmonary fibrosis: Clinical trials are the need of the hour. Lung India (2014) 0.75
Promising new treatment targets in patients with fibrosing lung disorders. World J Clin Cases (2014) 0.75
Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evid (2016) 0.75
The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): Diagnostic and Adjudication Processes. Chest (2015) 0.75
Safety and efficacy of bleomycin/pingyangmycin-containing chemotherapy regimens for malignant germ cell tumor patients in the female genital system. Oncotarget (2017) 0.75
Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. Clin Med Insights Circ Respir Pulm Med (2016) 0.75
A Case of Polymyxin b-Immobilized Fiber Column Treatment for Rapidly Progressive Interstitial Pneumonia Associated with Clinically Amyopathic Dermatomyositis. Case Rep Med (2013) 0.75
Reply: A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup? Am J Respir Crit Care Med (2013) 0.75
Pharmacogenetics and interstitial lung disease. Curr Opin Pulm Med (2016) 0.75
Prognosis of nonspecific interstitial pneumonia correlates with perivascular CD4+ T lymphocyte infiltration of the lung. BMC Pulm Med (2015) 0.75
Outcome Measures for Clinical Trials in Interstitial Lung Diseases. Curr Respir Med Rev (2016) 0.75
Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a single arm, non-randomized prospective clinical trial. Multidiscip Respir Med (2016) 0.75
Reply: rationale for anticoagulant therapy of pulmonary fibrosis. Am J Respir Crit Care Med (2014) 0.75
Evidence-based recommendations in idiopathic pulmonary fibrosis: a year is a long time in interstitial lung disease. Am J Respir Crit Care Med (2012) 0.75
Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis. JCI Insight (2017) 0.75
Diffuse alveolar hemorrhage in coumarin users: a fibrosing interstitial pneumonia trigger? Lung (2012) 0.75
Idiopathic Pulmonary Fibrosis: Data-driven Textural Analysis of Extent of Fibrosis at Baseline and 15-Month Follow-up. Radiology (2017) 0.75
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med (2000) 12.71
A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost (1993) 7.92
Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med (2001) 4.45
Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med (2001) 4.39
Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest (2005) 3.02
Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest (2011) 2.49
Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med (2001) 2.35
Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest (2009) 2.16
The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med (2008) 2.02
Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol (2008) 1.80
PARticipation in inflammation. J Clin Invest (2003) 1.70
Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation (2010) 1.68
A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials (2010) 1.59
A comparison of sample size methods for the logrank statistic. Stat Med (1992) 1.45
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir Res (2009) 1.34
Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost (2000) 1.33
Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med (2010) 1.14
Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J (2011) 1.07
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA (2005) 7.41
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med (2008) 4.33
The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med (2005) 4.25
Reduced length of hospital stay in colorectal surgery after implementation of an enhanced recovery protocol. Anesth Analg (2014) 4.19
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med (2010) 4.19
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med (2005) 3.83
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care (2007) 3.53
Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol (2003) 3.02
Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med (2005) 2.86
Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med (2008) 2.65
Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation (2006) 2.60
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol (2009) 2.58
Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 2.20
Comparative effectiveness of beta-blockers in elderly patients with heart failure. Arch Intern Med (2008) 2.15
Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.10
Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA (2007) 2.10
The solitary pulmonary nodule. Chest (2003) 2.09
A prospective multicenter study of competency metrics and educational interventions in the learning of bronchoscopy among new pulmonary fellows. Chest (2009) 1.97
An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med (2007) 1.91
A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis. PLoS One (2011) 1.87
Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2009) 1.80
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2014) 1.80
Native valve endocarditis due to coagulase-negative staphylococci: report of 99 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis (2004) 1.80
Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol (2007) 1.78
Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs. Health Aff (Millwood) (2008) 1.74
Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol (2005) 1.69
Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. J Am Coll Cardiol (2011) 1.68
Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest (2007) 1.66
Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res (2003) 1.59
Enhanced monocyte chemoattractant protein-3/CC chemokine ligand-7 in usual interstitial pneumonia. Am J Respir Crit Care Med (2004) 1.59
A generalized estimator of the attributable benefit of an optimal treatment regime. Biometrics (2009) 1.58
Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol (2009) 1.55
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med (2014) 1.54
Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Heart Rhythm (2010) 1.54
Influence of the Angioplasty Revascularization Investigation National Heart, Lung, and Blood Institute Diabetic Clinical Alert on practice patterns: results from the National Cardiovascular Network Database. Circulation (2003) 1.52
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med (2013) 1.51
Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia. Eur Respir J (2016) 1.51
Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2012) 1.44
National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J (2006) 1.43
Linking the National Cardiovascular Data Registry CathPCI Registry with Medicare claims data: validation of a longitudinal cohort of elderly patients undergoing cardiac catheterization. Circ Cardiovasc Qual Outcomes (2012) 1.42
Open-access biorepository for idiopathic pulmonary fibrosis. The way forward. Ann Am Thorac Soc (2014) 1.42
Challenges in enrollment of minority, pediatric, and geriatric patients in emergency and acute care clinical research. Ann Emerg Med (2008) 1.42
Focal adhesion kinase (FAK)-related non-kinase inhibits myofibroblast differentiation through differential MAPK activation in a FAK-dependent manner. J Biol Chem (2008) 1.42
Costs for heart failure with normal vs reduced ejection fraction. Arch Intern Med (2006) 1.36
The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged. J Biol Chem (2003) 1.32
Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study. Am Heart J (2007) 1.29
Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia. Am J Respir Crit Care Med (2007) 1.29
Smoking-related interstitial lung disease: radiologic-clinical-pathologic correlation. Radiographics (2008) 1.27
Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest (2014) 1.25
Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA (2013) 1.25
Safety of open food challenges in the office setting. Ann Allergy Asthma Immunol (2008) 1.24
TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med (2010) 1.21
Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. Circ Heart Fail (2013) 1.21
Human pulmonary fibroblasts exhibit altered interleukin-4 and interleukin-13 receptor subunit expression in idiopathic interstitial pneumonia. Am J Pathol (2004) 1.20
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer (2007) 1.14
A polyurethane cuffed endotracheal tube is associated with decreased rates of ventilator-associated pneumonia. J Crit Care (2010) 1.13
Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J (2005) 1.12
Use of surgery in patients with native valve infective endocarditis: results from the International Collaboration on Endocarditis Merged Database. Am Heart J (2005) 1.11
Prostaglandin E2 mediates IL-1beta-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors. J Immunol (2008) 1.11
Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts to immunodeficient mice. Am J Pathol (2007) 1.10
Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res (2013) 1.10
Development, deployment and usability of a point-of-care decision support system for chronic disease management using the recently-approved HL7 decision support service standard. Stud Health Technol Inform (2007) 1.08
Survival after coronary revascularization, with and without mitral valve surgery, in patients with ischemic mitral regurgitation. Circulation (2003) 1.08
Diagnosing fibrotic lung disease: when is high-resolution computed tomography sufficient to make a diagnosis of idiopathic pulmonary fibrosis? Respirology (2009) 1.07
Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. Am Heart J (2012) 1.06
Quality of life after late invasive therapy for occluded arteries. N Engl J Med (2009) 1.06
Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther (2002) 1.06
Interleukin-17-mediated immunopathogenesis in experimental hypersensitivity pneumonitis. Am J Respir Crit Care Med (2009) 1.06
A global ranking approach to end points in trials of mechanical circulatory support devices. J Card Fail (2008) 1.05
Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest (2013) 1.05
The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2008) 1.04
Perceptions of Medicaid beneficiaries regarding the usefulness of accessing personal health information and services through a patient Internet portal. AMIA Annu Symp Proc (2006) 1.04
Patient receipt and understanding of written information provided with isotretinoin and estrogen prescriptions. J Gen Intern Med (2007) 1.04
The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med (2012) 1.04
FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis. Am J Pathol (2013) 1.04